aibio
Financings ·
Lineage Cell Therapeutics closes second tranche, offering proceeds reach $30 million
Lineage received $6 million more after shareholders approved a sale to a director's affiliate. Milestone-linked warrants could add up to $36 million.
LCTX Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics (LCTX) news LCTX offering news
Latest Lineage Cell Therapeutics news
We have not published a story on Lineage Cell Therapeutics yet. When there is news, it will appear here.
What Lineage Cell Therapeutics does
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing cell replacement therapies for serious conditions that arise from the loss of critical cellular activity. It calls its approach Replace and Restore. Its most clinically advanced program is OpRegen (RG6501), an allogeneic retinal pigmented epithelial cell replacement therapy in Phase 2a development under a worldwide collaboration with F. Hoffman-La Roche Ltd. and Genentech, Inc., for geographic atrophy secondary to dry age-related macular degeneration. Its proprietary AlloSCOPE manufacturing platform starts from a single pluripotent cell line and can be applied across multiple programs to produce off-the-shelf allogeneic cell products. The pipeline also includes OPC1, an allogeneic oligodendrocyte progenitor cell therapy in Phase 1/2a development for spinal cord injuries, and ReSonance (ANP1), an auditory neuron progenitor cell therapy in preclinical development with William Demant Invest 2 Aps for auditory neuropathy. Other research programs address photoreceptor cell therapy for vision loss, islet cells for type 1 diabetes and an undisclosed allogeneic cell transplant target. The company may partner programs during early or late development.
| Product or program | What it is | Stage |
|---|---|---|
| OpRegen (RG6501) | Allogeneic RPE cell replacement therapy for geographic atrophy secondary to dry AMD | Phase 2a, under collaboration with Roche and Genentech |
| OPC1 | Allogeneic oligodendrocyte progenitor cell therapy for spinal cord injuries | Phase 1/2a |
| ReSonance (ANP1) | Allogeneic auditory neuron progenitor cell therapy for auditory neuropathy | Preclinical, under collaboration with William Demant Invest 2 Aps |
| PNC1 | Allogeneic photoreceptor cell therapy research initiative for vision loss | |
| ILT1 | Research initiative on large-scale production of pluripotent cells for islet cells in type 1 diabetes | |
| AlloSCOPE | Proprietary allogeneic cell manufacturing platform |
Lineage Cell Therapeutics annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $14.6 million | $9.5 million |
| Research and development | $17.7 million | $12.5 million |
| Net income (loss) | -$63.5 million | -$18.6 million |
| Cash from operations | -$18.9 million | -$23.1 million |
| Cash and equivalents | $40.8 million | $45.8 million |
| Short-term investments | $15.0 million | $2.0 million |
Questions about Lineage Cell Therapeutics
Has Lineage Cell Therapeutics raised money recently?
Our latest story on this, dated Jan 27, 2025: "Lineage Cell Therapeutics closes second tranche, offering proceeds reach $30 million". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Lineage Cell Therapeutics?
Lineage Cell Therapeutics, Inc. trades under the ticker LCTX on AMEX.
Where is Lineage Cell Therapeutics listed?
Lineage Cell Therapeutics, Inc. is listed on AMEX. Our directory also records these other listings: GETTEX:BT3; TASE:LCTX.
What is the SEC CIK of Lineage Cell Therapeutics?
The SEC Central Index Key (CIK) for Lineage Cell Therapeutics, Inc. is 876343. Its filings are on SEC EDGAR.
How many shares does Lineage Cell Therapeutics have outstanding?
252,907,464 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-06.
Which country or territory is Lineage Cell Therapeutics listed under?
Our directory records Lineage Cell Therapeutics, Inc. under United States.
What does Lineage Cell Therapeutics do?
Our directory classifies Lineage Cell Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of Lineage Cell Therapeutics?
The ISIN recorded for Lineage Cell Therapeutics, Inc. is US53566P1093.
Does aibio.space cover Lineage Cell Therapeutics?
aibio.space lists Lineage Cell Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Lineage Cell Therapeutics incorporated?
SEC records list its state or country of incorporation as CA.
What does Lineage Cell Therapeutics develop?
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing cell replacement therapies for serious conditions that arise from the loss of critical cellular activity. It calls its approach Replace and Restore.
What is OpRegen (RG6501) from Lineage Cell Therapeutics?
OpRegen (RG6501): Allogeneic RPE cell replacement therapy for geographic atrophy secondary to dry AMD Stage: Phase 2a, under collaboration with Roche and Genentech.
What is OPC1 from Lineage Cell Therapeutics?
OPC1: Allogeneic oligodendrocyte progenitor cell therapy for spinal cord injuries Stage: Phase 1/2a.
What was Lineage Cell Therapeutics's revenue last year?
$14.6 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Is Lineage Cell Therapeutics profitable?
Lineage Cell Therapeutics, Inc. reported a net loss of $63.5 million for the fiscal year ended Dec 31, 2025, and used $18.9 million of cash in operations, per its annual report to the SEC.
Investor discussion: Lineage Cell Therapeutics
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Financings
Filed a final prospectus for a securities offering. SEC Form 424B5. Source
- Financings
Reported a financing. SEC Form 8-K (Items 8.01). Source
- Legal
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
- Financings
Reported a financing. SEC Form 8-K (Items 5.07,7.01,8.01,9.01). Source
- Financings
Reported a financing. SEC Form 8-K (Items 1.01,7.01,8.01,9.01). Source
Stock chart
SEC filings and registration
- SEC name
- Lineage Cell Therapeutics, Inc.
- CIK
- 876343
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) (2836)
- US tickers
- LCTX (NYSE)
- State or country of incorporation
- CA
- Fiscal year ends
- December 31
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Business address
- 2173 SALK AVENUE, CARLSBAD, CA, 92008
- Phone
- 5105213390
- Shares outstanding
- 252,907,464 as of 2026-08-03 (10-Q filed 2026-08-06)
- Former names
- BIOTIME INC
Recent filings
Listing details
- Company
- Lineage Cell Therapeutics, Inc.
- Ticker
- LCTX
- Listing
- AMEX
- Country or territory
- United States
- Business scope
- Biotechnology
- ISIN
- US53566P1093
- Other listed symbols
- GETTEX:BT3; TASE:LCTX
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction